Open Access
Recent advances in heat shock proteins in cancer diagnosis, prognosis, metabolism and treatment
Publication type: Journal Article
Publication date: 2021-10-01
scimago Q1
wos Q1
SJR: 1.775
CiteScore: 12.8
Impact factor: 7.5
ISSN: 07533322, 19506007
PubMed ID:
34426258
General Medicine
Pharmacology
Abstract
Heat shock proteins (HSPs) are a group of proteins, also known as molecular chaperones, which participate in protein folding and maturation in response to stresses or high temperature. According to their molecular weights, mammalian HSPs are classified into HSP27, HSP40, HSP60, HSP70, HSP90, and large HSPs. Previous studies have revealed that HSPs play important roles in oncogenesis and malignant progression because they can modulate all six hallmark traits of cancer. Because of this, HSPs have been propelled into the spotlight as biomarkers for cancer diagnosis and prognosis, as well as an exciting anticancer drug target. However, the relationship between the expression level of HSPs and their activity and cancer diagnosis, prognosis, metabolism and treatment is not clear and has not been completely established. Herein, this review summarizes and discusses recent advances and perspectives in major HSPs as biomarkers for cancer diagnosis, as regulators for cancer metabolism or as therapeutic targets for cancer therapy, which may provide new directions to improve the accuracy of cancer diagnosis and develop more effective and safer anticancer therapeutics.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
6
7
8
|
|
|
International Journal of Molecular Sciences
8 publications, 9.41%
|
|
|
Cancers
5 publications, 5.88%
|
|
|
Cells
3 publications, 3.53%
|
|
|
Cell Stress and Chaperones
2 publications, 2.35%
|
|
|
Journal of Cancer Research and Clinical Oncology
2 publications, 2.35%
|
|
|
Journal of Biological Chemistry
2 publications, 2.35%
|
|
|
Cancer Letters
2 publications, 2.35%
|
|
|
Pharmaceutics
2 publications, 2.35%
|
|
|
Pharmaceuticals
1 publication, 1.18%
|
|
|
Nano Research
1 publication, 1.18%
|
|
|
Scientific Reports
1 publication, 1.18%
|
|
|
Molecular Medicine
1 publication, 1.18%
|
|
|
Biotechnology Advances
1 publication, 1.18%
|
|
|
International Journal of Pharmaceutics
1 publication, 1.18%
|
|
|
Talanta
1 publication, 1.18%
|
|
|
Experimental Gerontology
1 publication, 1.18%
|
|
|
Drug Resistance Updates
1 publication, 1.18%
|
|
|
Journal of Controlled Release
1 publication, 1.18%
|
|
|
Phytotherapy Research
1 publication, 1.18%
|
|
|
Journal of the National Cancer Institute. Monographs
1 publication, 1.18%
|
|
|
Cancer Medicine
1 publication, 1.18%
|
|
|
Journal of Cellular Biochemistry
1 publication, 1.18%
|
|
|
Frontiers in Cardiovascular Medicine
1 publication, 1.18%
|
|
|
Biomaterials Science
1 publication, 1.18%
|
|
|
Particulate Science and Technology
1 publication, 1.18%
|
|
|
Evidence-based Complementary and Alternative Medicine
1 publication, 1.18%
|
|
|
Lecture Notes in Electrical Engineering
1 publication, 1.18%
|
|
|
Applied Biochemistry and Microbiology
1 publication, 1.18%
|
|
|
Cell Reports
1 publication, 1.18%
|
|
|
1
2
3
4
5
6
7
8
|
Publishers
|
5
10
15
20
25
|
|
|
Elsevier
23 publications, 27.06%
|
|
|
MDPI
21 publications, 24.71%
|
|
|
Springer Nature
15 publications, 17.65%
|
|
|
Wiley
7 publications, 8.24%
|
|
|
Frontiers Media S.A.
3 publications, 3.53%
|
|
|
Royal Society of Chemistry (RSC)
2 publications, 2.35%
|
|
|
Taylor & Francis
2 publications, 2.35%
|
|
|
Pleiades Publishing
2 publications, 2.35%
|
|
|
American Chemical Society (ACS)
2 publications, 2.35%
|
|
|
American Society for Biochemistry and Molecular Biology
1 publication, 1.18%
|
|
|
Oxford University Press
1 publication, 1.18%
|
|
|
Hindawi Limited
1 publication, 1.18%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 1.18%
|
|
|
SciELO
1 publication, 1.18%
|
|
|
SAGE
1 publication, 1.18%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 1.18%
|
|
|
Spandidos Publications
1 publication, 1.18%
|
|
|
5
10
15
20
25
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
85
Total citations:
85
Citations from 2024:
42
(49.41%)
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Yang S., Xiao H., Li C. Recent advances in heat shock proteins in cancer diagnosis, prognosis, metabolism and treatment // Biomedicine and Pharmacotherapy. 2021. Vol. 142. p. 112074.
GOST all authors (up to 50)
Copy
Yang S., Xiao H., Li C. Recent advances in heat shock proteins in cancer diagnosis, prognosis, metabolism and treatment // Biomedicine and Pharmacotherapy. 2021. Vol. 142. p. 112074.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.biopha.2021.112074
UR - https://doi.org/10.1016/j.biopha.2021.112074
TI - Recent advances in heat shock proteins in cancer diagnosis, prognosis, metabolism and treatment
T2 - Biomedicine and Pharmacotherapy
AU - Yang, Shu-Xian
AU - Xiao, Haiyan
AU - Li, Cao
PY - 2021
DA - 2021/10/01
PB - Elsevier
SP - 112074
VL - 142
PMID - 34426258
SN - 0753-3322
SN - 1950-6007
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2021_Yang,
author = {Shu-Xian Yang and Haiyan Xiao and Cao Li},
title = {Recent advances in heat shock proteins in cancer diagnosis, prognosis, metabolism and treatment},
journal = {Biomedicine and Pharmacotherapy},
year = {2021},
volume = {142},
publisher = {Elsevier},
month = {oct},
url = {https://doi.org/10.1016/j.biopha.2021.112074},
pages = {112074},
doi = {10.1016/j.biopha.2021.112074}
}